Congressionally Directed Breast Cancer Research Program Breakthrough Award Levels 3 and 4 (12.27.17) 

September 26, 2017
By: Julie Poucher Harbin, Writer, DCI

DEADLINES EXTENDED! 

Funding Agency: Department of Defense 

The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are:

Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must be significant and move beyond an incremental advancement. Applications must articulate the pathway to making a clinical impact for individuals with, or at risk for, breast cancer, even if clinical impact is not an immediate outcome.

Research Scope: Research proposed under this award mechanism may be small- to large-scale projects, at different stages of idea and research development. Two different funding levels, based on the scope of the research, are available under this Program Announcement. The current Program Announcement discusses Funding Levels 3 and 4. Funding Levels 1 and 2 will be available under a different Program Announcement (W81XWH-17-BCRPBREAKTHROUGH2-FL12). It is the responsibility of the Principal Investigator (PI) to select the funding level that is most appropriate for the research proposed. The funding level should be selected based on the scope of the research project, rather than the amount of the budget.

The following are general descriptions, although not all-inclusive, of the scope of research projects that would be appropriate to propose under each funding level:

Funding Level 3: Advanced translational studies that have potential for near-term clinical investigation. Small-scale clinical trials may apply.

Funding Level 4: Large-scale projects that will transform and revolutionize the clinical management and/or prevention of breast cancer. Near-term clinical impact is expected. Human clinical testing is required. PIs are expected to have experience in successfully leading large-scale projects.

Funding Amount: $10,000,000

The anticipated direct costs budgeted for the entire period of performance for an FY17 BCRP Breakthrough Award Funding Level 3 will not exceed $2.5M or $4M if applying under the Partnering PI Option. The The anticipated direct costs budgeted for the entire period of performance for an FY17 BCRP Breakthrough Award Funding Level 3 will not exceed $2.5M or $4M if applying under the Partnering PI Option. The anticipated direct costs budgeted for the entire period of performance for an FY17 BCRP Breakthrough Award Funding Level 4 (single PI or Partnering PI Option) will not exceed $10M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

Areas of Interest: 

Considering the current breast cancer landscape and the BCRP’s vision to end breast cancer, all FY17 BCRP Breakthrough Award Levels 3 and 4 applications must address at least one of the following overarching challenges. Alternatively, with adequate justification, applications may identify and address another overarching challenge related to the breast cancer landscape. Justification must be provided in the application. • Prevent breast cancer (primary prevention) • Identify determinants of breast cancer initiation, risk, or susceptibility • Distinguish deadly from non-deadly breast cancers • Conquer the problems of overdiagnosis and overtreatment • Identify what drives breast cancer growth; determine how to stop it • Identify why some breast cancers become metastatic • Determine why/how breast cancer cells lie dormant for years and then re-emerge (recurrence); determine how to prevent recurrence • Revolutionize treatment regimens by replacing them with ones that are more effective, less toxic, and impact survival • Eliminate the mortality associated with metastatic breast cancer

Application Deadlines:  

Pre-Application Deadline: Oct. 6, 2017 (was Sep. 27)
Invitation to Submit an Application: November 1, 2017
Application Submission Deadline:  December 27, 2017 (was Dec. 21)

Eligibility: Faculty

Independent investigators at all academic levels (or equivalent) are eligible to submit an application. An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by, or affiliated with, an eligible organization.

Each investigator may submit only one Funding Level 3 pre-application as a PI or Initiating PI and may also submit only one Funding Level 4 pre-application as a PI or Initiating PI for this Breakthrough Award Levels 3 and 4 Program Announcement.

For more information: https://www.grants.gov/web/grants/view-opportunity.html?oppId=296274